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SUMMARY
This study reveals that high-copy satellite II (HSATII)
sequences in the human genome can bind and
impact distribution of chromatin regulatory proteins
and that this goes awry in cancer. In many cancers,
master regulatory proteins form two types of can-
cer-specific nuclear bodies, caused by locus-spe-
cific deregulation of HSATII. DNA demethylation at
the 1q12 mega-satellite, common in cancer, causes
PRC1 aggregation into prominent Cancer-Associ-
ated Polycomb (CAP) bodies. These loci remain
silent, whereas HSATII loci with reduced PRC1
become derepressed, reflecting imbalanced distri-
bution of UbH2A on these and other PcG-regulated
loci. Large nuclear foci of HSATII RNA form and
sequester copious MeCP2 into Cancer-Associated
Satellite Transcript (CAST) bodies. Hence, HSATII
DNA and RNA have an exceptional capacity to act
as molecular sponges and sequester chromatin reg-
ulatory proteins into abnormal nuclear bodies in can-
cer. The compartmentalization of regulatory proteins
within nuclear structure, triggered by demethylation
of ‘‘junk’’ repeats, raises the possibility that this con-
tributes to further compromise of the epigenome and
neoplastic progression.
INTRODUCTION
Epigenetic changes are recognized as a major player in tumori-
genesis (Feinberg, 2014; Sandoval and Esteller, 2012). Although
attention has been focused on methylation and silencing of
tumor suppressor genes, this often occurs concomitant with
loss of methylation from other genomic regions, including peri-
centric satellites. High-copy tandem satellites repeat families
(alpha, beta, SATI, II, III) constitute15% of the human genome.
Alpha-satellite (a-SAT) is at the centromere of all chromosomes,
and satellite III (HSATIII) on chromosome 9 (chr9) is linked to the
heat shock response and nuclear stress bodies (Biamonti and
Vourc’h, 2010). However, many repeats are considered mere
evolutionary relics and have been poorly studied. Perhaps the
best example of this is human satellite II (HSATII), an exceptionally
high-copy repeatwith no raisond’etre. Small blocks ofHSATII are
found on the pericentromeres of 11 human chromosomes (chr2,
5, 7, 10, 13, 14, 15, 17, 21, 22, and Y), but 1q12 on chr1, and to
a lesser extent 6q11on chr16, carries very large (5–6Mb) blocks
of this 26-bp tandem repeat. There is frequent loss of methyl-
ation of HSATII in cancer (Ehrlich, 2009), but any significance of
this is unknown. HSATII remains one of the most prominent but
poorly studied features of the human genome.
Peri/centric heterochromatin is regulated by the polycomb
group (PcG) complexes PRC1 and PRC2, which also control
most early developmental pathways and are commonly misre-
gulated in cancer (Simon and Kingston, 2009). Peri/centric het-
erochromatin is generally silent but can be expressed in relation
to cell cycle, heat shock, and stress (Hall et al., 2012). When we
found an unexpected association of the BRCA1 tumor suppres-
sor with satellite DNA during its replication (Pageau and Law-
rence, 2006), we hypothesized that satellitesmight be expressed
in cancer (Pageau et al., 2007). Studies subsequently reported
peri/centric satellite expression in several cancers (Eymery
et al., 2009; Ting et al., 2011; Zhu et al., 2011), but many ques-
tions remain as to the extent, specificity, and significance of
this. Does it reflect broad non-specific heterochromatic insta-
bility across all satellites, or might it show family or locus
specificity? How does it arise, and, perhaps most importantly,
does it have any impact on the cell? Study of satellites is limited
using standard genomic approaches, as evidenced by the lack
of the extraordinarily large 1q12 HSATII in the human genome
database. Here, we use an approach to study satellite DNA
and RNA, which preserves molecular information within cell
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and nuclear/chromosome structure and allows analysis not
only of specific repeat families, but also of specific loci of a given
family within single cells.
Our results support a paradigm for the significance of changes
to satellite heterochromatin: the million or more copies of HSATII
per cell have a pronounced capacity, at both the DNA and RNA
levels, to absorb and impact the distribution of key epigenetic
regulators across the nuclear genome. This goes awry in cancer
and is linked to the common demethylation of HSATII, and the
‘‘mega-satellite’’ at 1q12 may play a singular role.
RESULTS
Aberrant Nuclear Foci of Satellite RNA Are Common in a
Wide Array of Tumor Types
Wepreviously showed that a CoT-1 (highly repetitive) DNA probe
(Britten and Kohne, 1968) detects an evenly distributed RNA
signal across the euchromatic nucleoplasm by fluorescence
in situ hybridization (FISH) (Figure 1A) (Hall et al., 2002, 2014).
However, we noted some cell samples also contained very
prominent CoT-1 RNA foci (Figures 1B, 1C, S1A, and S1B),
which can be quite large (compare to XIST RNA; Figure 1D). In
22 cell lines surveyed, CoT-1 RNA foci were in 11 of 14
neoplastic lines but none of eight normals (Table S1).
As CoT-1 is heterogeneous, probes to different repeat families
(see Supplemental Information) were used to identify specific
repeats within the RNA foci. Although interspersed LINE1 or
Alu (SINE) repeats were not present in CoT-1 RNA foci (Figures
S1C and S1D), a-SAT (Figures S1E and S1F) and HSATII were
(Figure 1E). These RNA foci are nuclear restricted, and several
observations affirm these foci are single-stranded RNA: detec-
tion without DNA denaturation (which will not detect even these
highly abundant DNA sequences) (Lawrence et al., 1988), loss of
signal with RNase (Figures S1G, S1H, S2D, and S2E) or NaOH,
specificity for certain cell lines, absence from mitotic chromo-
somes, and release of these HSATII RNA ‘‘bodies’’ into the cyto-
plasm of mitotic cells (Figures 6G and S2F).
We examined a-Sat and HSATII expression by RNA FISH in 14
cancer cell lines and eight non-cancer lines, nine human effusion
samples, and 44 human solid tumors (with matched normal
where available) for a wide array of tumor types (Table S1). Given
that RNA preservation in pathology samples can be variable, we
used poly(A) RNA as a positive control. Satellite RNA foci were
detectable in over half of the tissue samples (solid tumor and
effusion) (Figures 1F–1H) and ten of 14 cancer lines but in none
of the normal tissue or lines (Table S1). Thus, aberrant nuclear
satellite RNA foci are common in human cancers in vivo and
in vitro.
Satellite Dysregulation Is Family Specific, Primarily
HSATII, and Not Tied to BRCA1 Status
Does this misregulation reflect a generalized failure to maintain
silencing on all satellites or preferentially impact a specific repeat
family or locus? This has implications for whether misregulated
satellites are a consequence or contributor to neoplasia.
The conserved a-SAT repeat is easily distinguished on all
chromosomes. However, due to sequence similarity we tested
a number of probes and labeling strategies to identify probes
(and conditions) that discriminate HSATIII on chr9 from HSATII
on other chromosomes (Figures S1I–S1M). The HSATIII probe,
and an antibody to Heat shock Factor 1 (HSF1), confirmed that
the RNA expressed in these unstressed cancer cells was HSATII
(Figures S1I–S1O) (details in Supplemental Information).
Numerous small dim nuclear foci of human a-SAT RNA were
visible in all normal cell lines examined, including proliferative
fibroblasts and post-mitotic myotube nuclei (Figures S2A–S2F;
Table S1). Since our initial observations, centric satellite RNAs
were reported at very low levels in normal cells (Bierhoff et al.,
2014), supporting the accuracy and sensitivity of our in situ
approach. However, these small foci were still distinct from the
larger a-Sat foci that overlapped CoT-1 RNA foci in some cancer
cells (Figures S2G–S2J).
In contrast to a-sat, HSATII RNA is essentially undetectable in
normal cells using multiple HSATII probes (see Supplemental In-
formation) (Figures 1I–1N; Table S1). Normal cells only occasion-
ally had a tiny pinpoint of HSATII RNA fluorescence detectable
with digital imaging. Conversely, HSATII RNA foci were quite large
in cancer nuclei and distinct enough to identify a single cell as
cancerous. This was affirmed by quantitative digital imaging
(Figures 1L–1N) and showed U2OS cells with 175-fold more
HSATII RNA than normal cells (Figure 1N). The intensity and
size (0.4–1 mm) of these RNA conglomerations (Figure 1D; Table
S3) indicate extremely high copies of the 26-bpHSATII sequence.
Examining the frequency of a-Sat and HSATII overexpression,
we found a-SAT RNA foci were seen in only two of nine cancer
lines (HT1080 and MDA-MB-436) (Figures S1E and S1F;
Figure 1. Cancer Cells Contain Bright Nuclear HSATII RNA Foci, Not Normal Cells
(A) Primary fibroblasts with normal nucleoplasmic CoT-1 RNA signal.
(B and C) Cancer nuclei with large CoT-1 RNA foci. (A and B are same scale. Bar, 10 mm.)
(D) Cot-1 RNA foci versus the XIST RNA territory.
(E) HSATII RNA overlaps Cot-1 RNA foci. Scale bar, 10 mm. Red and green channel is separated at right.
(F) H&E stain of breast tumor #2334T.
(G) HSATII RNA foci in cancerous cells of breast tumor #2334T. Insets show DNA channel and close up of region in (G).
(H) Mutant-P53 staining labels cancerous cells in #2334T tissue. DNA channel is separated at right.
(I–K) Cancer cells (I and J) have aberrant HSATII RNA foci; normal cells (K) do not. Green channel for boxed regions is separated at right. Exposure, magnification,
and scale bar (10 mm) are same for all images.
(L) Single brightest pixel in 50 cells of two cell lines (IMR90/normal and U2OS/cancer). Threshold for each is three times the averageminimum pixel intensity. Most
normal cells fall below threshold, but few cancer cells do.
(M) Line scans through three cancer cells (HCC-1937, MCF-7, and PC3) and two normal nuclei (Tig-1 and WS1) show the size (width) and intensity (height) of
HSATII RNA foci.
(N) Total HSATII RNA signal above threshold for cancer (U2OS) and normal (IMR90) nuclei were quantified (integrated intensity), and the average was plotted.
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Table S1) and 25% of tumor samples, whereas HSATII RNA was
found, in eight of nine cancer lines (70%–100%of cells) and about
half of tumor and effusion samples (Table S1). Moreover, 50% of
tumors with satellite RNA foci had HSATII exclusively (11/22
samples tested for both), and only 9% had a-SAT alone (and
41%with both). Zhu et al. (2011) reported a-SAT RNA expression
in BRCA1/ breast cancers and concluded loss of BRCA1 spe-
cifically causes this (due to loss of UbH2A deposition). However,
BRCA1+ tumors were never examined, and our results show
a-SAT RNA is neither specific to breast tumors nor to BRCA1/
tumors (Table S1), with two of three breast tumors testing normal
for BRCA1 still exhibiting satellite RNA foci.
Thus, we find the HSATII family is preferentially expressed in
cancer, and satellite expression (a-Sat or HSATII) does not
closely correlate with BRCA1 status. Since the difference be-
tween normal and cancer cells is most marked for HSATII
RNA, we focus on HSATII for the rest of this study.
Importantly, in many (40%) HSATII positive tumors, HSATII
RNA foci were consistently present in essentially all (Figures
1F–1H) or most of the tumor cells, suggesting an early event.
This, together with the specificity for HSATII, suggests satellite
deregulation is not necessarily a sporadic consequence of
neoplasia.
PRC1 Redistributes into Large Cancer-Associated
Polycomb Bodies on 1q12, which Remains Repressed
We examined PolycombGroup (PcG) proteins, known to repress
heterochromatin (including satellites), and that are implicated in
cancer pathogenesis (Sauvageau and Sauvageau, 2010).
Staining for BMI-1, RING1B and Phc1 (PRC1), and EED and
EZH2 (PRC2) revealed PRC1 is aberrantly distributed in cancer
cells (Figures 2 and S2K) but generally not PRC2 (Figure S2L).
BMI-1 labels a few prominent nuclear bodies in 88% of
neoplastic lines and 44% of primary tumor samples but not
any normal tissues/lines (Figures 2A–2G; Table S2). Since com-
ponents of PRC1 can vary with cell type, these numbers (using
BMI-1) may underestimate the frequency of PRC1 in these
bodies. The large (0.4–1.5 mm) BMI-1 ‘‘bodies’’ were often
20-fold brighter than the surrounding nucleoplasm, whereas
most normal cells had hundreds of tiny punctates (Figures 2H–
2L). The most prominent BMI-1 foci in non-cancer cells (e.g.,
immortalized retinal pigment epithelium [RPE] cells) had at
most a ‘‘contrast ratio’’ of just 4:1 (Figures 2I and 2K). Impor-
tantly, the large cancer-associated PRC1 bodies consistently
(100%) and precisely co-localize with 1q12 HSATII DNA (and
to a lesser extent HSATII on chr16q11) (Figure 3A).
Our findings establish that these large PRC1 aggregates on
1q12 are not normal nuclear structures but a epigenetic hallmark
of cancer. Numerous small PcG puncta, widely dispersed in the
nucleoplasm (termed ‘‘PcG bodies’’), are found in all normal cells
from Drosophila to humans and are reported to help regulate
gene expression (Bantignies and Cavalli, 2011; Geyer et al.,
2011). PcG bodies have often been studied in cancer cells
(widely assumed to model normal nuclear structures) (Dundr,
2012), where it was noted cancer and normal cells might differ
in the number and size of their ‘‘PcG bodies’’ (Saurin et al.,
1998). However, our analysis establishes that the few prominent
bodies in cancer are a completely different structure, with
different biological significance. To avoid confusion with the
small, numerous, and widely distributed PcG puncta in normal
human cells, often referred to as ‘‘PcG bodies,’’ we refer to these
large conglomerations of PRC1 proteins that specifically ‘‘cap’’
the HSATII locus at 1q12 in cancer cells as ‘‘CAP’’ bodies, for
‘‘cancer-associated Polycomb’’ bodies.
We next examined the relationship between HSATII RNA foci
and PRC1 accumulation into bodies, with two alternate possibil-
ities: HSATII RNA might recruit PRC1 to 1q12, as do other
ncRNAs, such as XIST, or enrichment of PRC1 at 1q12 might
maintain repression, while other loci, in the nucleoplasm with
lower levels of PRC1, may become derepressed. Results show
that the latter consistently occurs; HSATII RNA foci and CAP
bodies are spatially separated (0% overlapping, 6% adjacent,
and 94%no association) (Figures 3B–3D), and sequential hybrid-
ization to HSATII RNA and DNA (Byron et al., 2013) indicates that
RNA foci emanate from small or mediumHSATII DNA loci but not
the largest HSATII loci of 1q12 (Figure 3E). Importantly, when
CAP bodies and HSATII RNA foci are both detected in a given tu-
mor, they are typically in the same nuclei, suggesting a relation-
ship. For example, in breast tumor #2334T, 80% CAP positive
nuclei also contained RNA foci (e.g., Figure 3D), which is likely
an underestimate since nuclei in the tissue are sliced.
Locus-Specific HSATII Sequence Subtypes Exist and
May Underlie Differences in PRC1 Accumulation or
Deregulation in Cancer
The different biological behaviors of HSATII loci raise the ques-
tion of whether there are variations in HSATII sequences at
different loci. Since most HSATII sequence is not in the human
genome build (hg19) (particularly 1q12), and it is difficult to
establish locus specificity of small tandem repeats by sequence
data, in situ hybridization allows us to investigate whether spe-
cific sequences are enriched at specific loci.
As detailed in the Supplemental Information, we examined a
series of probes representing different permutations of divergent
HSATII sequences, under varying hybridization stringencies.
Because the 1q12 locus is so large, most sequences found on
other chromosomes cross-hybridize to 1q12 and vice versa.
However, from the larger pUC1.77 cloned sequence from 1q12
we identified a smaller 160-bp PCR-generated sequence
(Sat2-160) that showed specific hybridization to 1q12, with slight
detection of 16q11. This probe did not detect HSATII RNA and
correlated strongly with BMI-1 aggregates (Figures S2M–S2O),
consistent with the above results. While there is no known
consensus sequence for mammalian PRC1 binding, this de-
monstrates that distinct subsets of HSATII sequences charac-
terize different loci, which likely contributes to distinct biological
behavior.
A separate question was whether we could identify specific
HSATII sequences/loci that are expressed. As summarized in
the Supplemental Information, we identified an expressed
sequence by RT-PCR (Figure S3A) that only labeled one to two
RNA foci in U2OS nuclei (by RNA FISH), which have an unusually
high number of RNA foci detected with the broader Sat2-24 LNA
probe (Figures 3E and 3F; Table S3), suggesting locus specificity
of the PCRprobe. This probe also labeled themore typical one to
two RNA foci detected by the permissive LNA probe in tumor
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tissues (Figure 3G). We tentatively mapped the sequence to
chromosome 7 (using hg19); however, since the probe labeled
more than one chromosome by DNA FISH, specific centromere
probes were used to confirm expression from chromosome 7
(Figure 3H). Of five tumor samples that scored high for HSATII
RNA, three expressed this sequence (now called Sat2-7) (three
positive breast tumors: #0853, #2004, and #2334, and two nega-
tive stomach tumors: #2539 and #2210). We also found HSATII
sequences from chr7 are also one of the more commonly ex-
pressed sequences in a pancreatic cancer deep sequencing
database (SRX056914) (Figure S3B), suggesting the chr7 locus
may be commonly misregulated in some cancers.
Figure 2. BMI-1 Aggregates in Large Aberrant Foci that Form Nuclear Bodies
(A and B) BMI-1 protein accumulates into bodies in cancer cells.
(C and D) Normal fibroblasts only have faint punctate nucleoplasmic signal. Red channel enhanced at right. Exposures are the same for (A)–(C).
(E) Cancer cell lines contain BMI-1 bodies, while non-cancer lines do not.
(F) Normal human tissue with uniform punctate distribution of BMI-1.
(G) The matched tumor sample contains BMI-1 bodies.
(H–J) Low nucleoplasmic BMI-1 in fibroblasts (H), slightly higher levels in telomerase immortalized RPE cells (I), and large accumulations in cancer cells (J), with
concomitant reduction in nucleoplasmic signal. (H–J are the same scale.)
(K and L) BMI-1 line scans of the same cells in (H)–(J).
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These findings demonstrate that there is a locus-specific dis-
tribution of HSATII sequence subtypes on different loci that may
underlie differences in biological behavior. Further, the dysregu-
lation of HSATII in cancer samples is not stochastic nor indis-
criminate but often shows locus and sequence specificity for a
given tumor (e.g., Table S3). The HSATII locus at 1q12 con-
sistently nucleates large CAP bodies and is marked by specific
subtypes of HSATII not detected in RNA, whereas the Sat2-7
sequence we identified on chr7p11 appears to be specifically
expressed in several tumors studied here.
HSATII Changes Link to Broader Epigenetic Instability in
Cancer from DNA Demethylation to UbH2A Distribution
We investigated whether changes in HSATII and CAP body
formation relate to broader epigenetic instability in cancer and
found evidence they do, both in terms of their cause but
also likely their consequences. DNA methylation is common in
Figure 3. PRC1 Aggregates on HSATII DNA
at 1q12Maintaining Repression, while Other
Loci Become Derepressed
(A) The pUC1.77 probe labels HSATII on chr1 and
some on chr16 (arrows) and correlates with BMI-1
‘‘CAP’’ bodies. Channels from outlined region are
separated at right.
(B and C) CAP bodies and HSATII RNA are
mutually exclusive. Red and green channels of (B)
at right.
(D) CAP bodies and HSATII RNA foci in breast
tumor tissue.
(E) HSATII RNA is expressed from small HSATII loci
and not from the large 1q12 loci. Small loci are
visible when DNA signal (of outlined region) is
separated and enhanced at right. HSATII RNA
accumulates adjacent to DNA loci (arrows).
(F and G) Sat2-7 probe labels only one to two RNA
foci in U2OS cells (F) or in breast tumor #2334T (G).
(H) chr7-specific centromere probe verifies Sat2-7
RNA is expressed from chr7.
cancer, and HSATII demethylation at
1q12 is a frequent and often early change
(Ehrlich, 2009). We therefore tested the
effects of inducing DNA demethylation
on HSATII expression or potentially redis-
tribution of PRC1.
We first examined cells of the rare
and fatal immunodeficiency-centromere
instability-facial anomalies (ICF) syn-
drome,where aDNMT3Bmutation causes
HSATII demethylation (Walton et al.,
2014), and found PRC1 accumulated in
large bodies that ‘‘cap’’ 1q12 in 61% of
the ICF fibroblasts (Figures 4E, S3C, and
S3D). We next treated normal human
fibroblasts with 5-aza-20-deoxycytidine,
which we previously confirmed demethy-
lates HSATII in these cells (Swanson
et al., 2013). Remarkably, within 24 hr
PRC1 accumulates into one to two large
bodies over 1q12 (Figures 4A–4C). Longer treatment increased
the number of cells affected (day 1 = 15%, day 3 = 52%, day
8 = 80%), and the number of bodies/cell (from two to four, repre-
senting accumulation on chr16q11). After several days, a subset
of cells (5%–10%) began to express HSATII RNA from other
loci (Figure 4D). Thus, loss of cytosine methylation on HSATII trig-
gersmassive recruitment of repressive PRC1 to 1q12, while other
loci eventually become derepressed.
Transient activity of PRC2 HMTase EZH2 is required to recruit
PRC1 (Herna´ndez-Mun˜oz et al., 2005). No consistent accumula-
tion of EZH2 was seen on 1q12 in cancer cells (Figure S2L) nor
following 5-aza2d treatment (Figure 4F), but an increase in nucle-
oplasmic H3K27me3 was seen (not limited to nor enriched on
pericentromeres) (Figures 4G and 4H), suggesting PRC2 activa-
tion. Inhibition of EZH2 (3-deazaneplanocin) during 5-aza-2d
treatment showed reduced H3K27me3 staining (confirming
EZH2 inhibition) (Figure 4I) and slowed/reduced CAP body
2948 Cell Reports 18, 2943–2956, March 21, 2017
formation (Figure 4J), suggesting EZH2/PRC2 activity is likely
involved in CAP body formation.
Corralling PRC1 into CAP bodies likely reduces its level else-
where, which can be seen by immunofluorescence (IF) in U2OS
cells (Figure 2J), at low (103) magnification in tumor sections (Fig-
ures 5A and 5B) and can be measured by line scan, when
comparing neighboring nuclei with and without CAP bodies (Fig-
ures 5C–5E; renal tumor). These findings point to a biological sig-
nificance for satellite demethylation in human cancers, due to the
marked capacity of this extremely high-copy repeat at 1q12, to
act as a molecular ‘‘sponge,’’ thereby impacting compartmental-
ization and accessibility of important nuclear factors.
To assess potential downstream effects of PRC1 redistribution
into CAP bodies, we examined UbH2A distribution (laid down by
PRC1), by chromatin immunoprecipitation (ChIP), in cancer and
normal cells. Reads mapping to HSATII increased sharply in
cancer cells, from 8% in normal Tig-1 fibroblasts to 37% in
U2OS osteosarcoma cells (Figure 5F). This is consistent with
PRC1 accumulation at 1q12, which would dominate the HSATII
sequence population. The distribution of UbH2A on 1q12 (Sat2-
160) versus chr7 (Sat2-7) satellites in normal cells is similar (since
both loci are repressed), whereas in U2OS cancer cells the 1q12
sequences become disproportionately enriched for UbH2A over
the expressed chr7 sequence (Figures 5G and S3E). Throughout
the broader epigenome, UbH2A distributed more uniformally in
Tigs (Figure 5H), whereas in U2OS more sequences deviate
from average, particularly at the low ends (Figure 5I). Gene
ontology analysis for genes with reduced UbH2A (4-fold or
Figure 4. CAP Bodies Are Induced by DNA Demethylation and PRC2 Activity
(A and B) Fibroblasts treated with 5aza-d form CAP bodies. Red channel is separated in (B).
(C) CAP bodies form over 1q12 in demethylated fibroblasts. Insets show colors separated for top body.
(D) HSATII is expressed following longer 5aza-d treatment. Inset shows green channel of outlined region.
(E) CAP bodies are present in ICF cell nuclei. Insets show color channels separated for CAP body.
(F) EZH2 (PRC2) does not aggregate in CAP bodies following 5-aza.
(G) Low-level H3K27me in controls, with enrichment on the inactive X chromosome.
(H) Increased H3K27me following 5-aza treatment.
(I) H3K27me levels reduced with simultaneous treatment with EZH2-inhibitor and 5-aza. The exposures are equal for (G)–(I).
(J) Number of cells with CAP bodies on days 3 and 5 following treatment with 5-aza (D3-A and D5-A) or 5-aza and EZH2-inhibitor (D3-A/Ei and D5-A/Ei).
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Figure 5. CAP Bodies Sequester PRC1 Affecting Genomic Distribution of UbH2A
(A) Low-magnification (103) view of BMI-1 in tumor tissue.
(B) Magnification of area in box of (A) shows cells with CAP bodies (arrows) and reduced nucleoplasmic BMI-1.
(C–E) Tumor cells with CAP bodies have reduced nucleoplasmic BMI-1 compared to neighboring cells lacking CAP bodies. Green channel separated in (D) and
line scan of cell 1 and 2 (E) are shown.
(F) ChIP-seq: total HSATII reads with UbH2A in cancer versus normal cells.
(G) ChIP-seq: UbH2A levels on expressed (Sat2-7) versus repressed (1q12) HSATII sequences in normal and cancer cells (total reads Figure S3E).
(H and I) ChIP-seq: distribution of UbH2A across the genome in normal (H) and cancer (I) cells.
(J) ChIP-PCR: UbH2A enrichment on 1q12, HoxC5, and b-actin loci before and after 5aza treatment.
(K) RING1B/RNF2 on the EGLN3 gene (involved in hereditary breast and ovarian cancer) in cancer cells and normal foreskin and breast fibroblasts.
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greater) in cancer cells suggested effects on genes involved in
neural differentiation (Table S4A), consistent with the known role
of BMI-1 (Corley and Kroll, 2015). Ting et al. also noted increased
neural gene expression, a known poor prognostic indicator, was
increased in cancers expressing HSATII (Ting et al., 2011). We
also examined PRC1 distribution in published ChIP sequencing
(ChIP-seq) (datasets for RING1B/RNF2) (Pemberton et al., 2014;
Rai et al., 2015) and found an increase in HSATII reads pulled
down in cancer compared to normal and proportionally more on
1q12 (Sat2-160) than chr7 (Sat2-7) (Figure S3F). The genes that
lost RING1B in cancer were also enriched for genes important
to carcinogenesis (Table S4B; Figure 5K), illustrating how redistri-
bution of PCR1 away from canonical genes could contribute to
tumorigenesis (Wang et al., 2015).
We also used ChIP-PCR to examine UbH2A levels on
three specific sequences in fibroblasts induced to form CAP
bodies with 5-aza. UbH2A was again clearly increased on the
1q12 (Sat2-160), whereas HoxC5, an established PcG-regulated
gene, demonstrated a corresponding sharp loss of UbH2A,
with no significant change in the b-actin housekeeping gene
(Figure 5J). These results further support that redistribution of
PRC1 proteins into CAP bodies is associated with reduced
access to repressive factors elsewhere, impacting UbH2A levels
and making genes more vulnerable to derepression over time
(e.g., HSATII at chr7).
MeCP2 Accumulates with HSATII RNA Transcripts into
Cancer-Associated Bodies
Since HSATII DNA repeats can ‘‘sponge-up’’ PRC1, it follows
that the similarly large HSATII RNA foci, containing likely millions
of copies of this small repeat, might likewise sequester specific
RNA-binding or regulatory factors, potentially similar to ‘‘Toxic
repeat RNAs’’ in other human diseases (see Discussion).
Therefore, we examined whether HSATII RNA foci might
accumulate MBNL1 (sequestered in repeat RNA in myotonic
dystrophy type I), which it did not, nor did HSATII RNA overlap
the PNC domain that sequesters proteins in many cancers
(Wen et al., 2013). Surprisingly, we discovered the methyl-DNA
binding protein, MeCP2, is found in large nuclear bodies that
precisely overlap the HSATII RNA foci. These large MeCP2 foci
(Figure 6A) are distinct from the broadly distributed small puncta
in normal cells (Figure 6B) and can be seen homogeneously
distributed throughout many tumors at low magnification (Fig-
ures S3G–S3I). We initially examined MeCP2 due to its capacity
to bind methylated DNA, and, although MeCP2 foci were similar
in size and number to both HSATII RNA foci and CAP bodies,
detailed analysis clearly showed they were associated with the
RNA, not DNA (Figures 6C–6F) (using two different antibodies
and several cancer samples). For example, MeCP2 exactly over-
laps HSATII RNA foci (Figure 6D), and since HSATII RNA foci are
immediately adjacent to the DNA locus (Figure 3E) MeCP2 is
not over the DNA. In addition, MeCP2 continues to overlap
HSATII RNA foci when the ‘‘body’’ enters the cytoplasm at
mitosis (Figures 6G and 6H).
We further show that MeCP2 and HSATII RNA co-immunopre-
cipitate from cancer cells by RNA immunoprecipitation (RIP).
HSATII RNA was consistently enriched in MeCP2 pull-downs
over immunoglobulin G (IgG) controls (Figure 6I), whereas
a-SAT RNA was not. RIP with MBNL1 did not pull down HSATII
RNA (confirming in situ results), while Sin3A, a transcriptional
regulator that can complex with MeCP2 (Jones et al., 1998),
did pull it down in some experiments. Using the RNA pulled
down by MeCP2 (or SIN3A) as probes, we detected HSATII
RNA foci in cancer cells by RNA FISH (Figures 6J and 6K).
Thus, the RNA foci of HSATII are not inert but also can bind
and impact distribution of epigenetic factors. We term these
large round aggregates of HSATII RNA with MeCP2 ‘‘cancer-
associated satellite transcript’’ (CAST) bodies and identify
them as another unique hallmark of cancer cells (in vitro and
in vivo).
MeCP2 is known to repress expression of LINE1 elements
(Erwin et al., 2014), which are inappropriately expressed in
cancer (Rodic and Burns, 2013). We recently showed that L1
sequences are a major part of the repeat-rich ‘‘CoT-1 RNA’’
that associates with euchromatin and may serve to maintain
open chromatin (Hall et al., 2014). The peripheral heterochromat-
in compartment in most normal cells characteristically lacks this
L1-rich CoT-1 RNA (Figures S3J and S3K), reflecting a stable
heterochromatic state. However, in cancer cells, CoT-1/L1
RNA is detected throughout this peripheral compartment, indi-
cating compromise of this heterochromatin (Figures S3L and
S3M; Pageau et al., 2007). In addition, we find U2OS tumor cells
havemore L1 RNA foci in nuclei compared to normal cells (Tig-1)
(Figure 6L), consistent with other reports of L1 activation in
cancers. Hence, the aberrant distribution of MeCP2 in cancer
nuclear structure may be relevant to broader changes in cancer
expression patterns.
Finally, we did not find evidence that HSATII RNA expression
leads to massive tandem expansion of HSATII DNA loci, as a
recent report suggests (Bersani et al., 2015). These authors
postulate that HSATII cDNA (via reverse-transcription of RNA)
is re-incorporated into and amplifies existing HSATII loci (e.g.,
up to 25-fold), since they saw no change in the number loci by
DNA FISH. However, the relative size and intensity of DNA
FISH signals is proportional to target size and much smaller dif-
ferences (2- to 3-fold) are easily discernible (Lawrence et al.,
1988). Using FISH and microfluorimetry to quantify the HSATII
DNA signals in normal and cancer cells, we found no substantial
differences in size, intensity, number of signals, or total HSATII
signal (Figure 6M). This was quantified in U2OS osteosarcoma,
but similar results were observed in other cancers. We detect a
slight increase in total HSATII DNA in U2OS, due to an extra
copy of the large 1q12 satellite (not tandem amplification), as
evident in Figure 3A.
The model and legend in Figure 7 summarize and integrate
several major findings in cancer nuclear structure and the epi-
genome, which we show are connected to complex and locus-
specific biology of HSATII.
DISCUSSION
This work demonstrates multiple properties of cancer cell
nuclear structure, with implications for epigenetic changes in
cancer and at the same time points to the unanticipated biolog-
ical importance of HSATII DNA, a large, unexplored component
of human genomes. We show that HSATII RNA accumulates in
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large nuclear foci in over half of all human cancers examined.
This occurs both in vivo and in vitro and is satellite family and lo-
cus specific. We also show an unexpected relationship between
Figure 6. MeCP2 Accumulates with HSATII
RNA into CAST Bodies
(A and B) MeCP2 bodies in breast cancer (A) and
matched normal samples (B).
(C) MeCP2 bodies are coincident with HSATII RNA
foci. Insets show colors separated for box.
(D) Line scan of nucleus in (C).
(E and F) MeCP2 and HSATII RNA in cultured
cancer cells (E) and tumor tissue (F). Insets show
colors separated for image or outlined region.
(G and H) HSATII RNA foci released to cytoplasm
in mitotic cells (G) are still associated with MeCP2
(H). Insets show colors separated for CAST body
(arrow).
(I) RNA-IP: HSATII RNA is pulled down with
MeCP2 and SIN3A but not MBNL1.
(J and K) HSATII probes made from MeCP2 (J) or
SIN3A (K) RIP labels same HSATII RNA foci in
cancer nuclei.
(L) Average number of L1 RNA foci per nucleus in
cancer and normal cells.
(M) Average integrated intensity of HSATII DNA
FISH signal in normal (Tig-1) and cancer (U2OS
and PC3) cells using two different probes (‘‘SatII
Fitc’’ = Sat2-59nt probe and ‘‘SatII LNA’’ = Sat2-
24nt LNA probe).
a specific HSATII DNA locus (1q12)
and PRC1 distribution in cancer, directly
related to DNA demethylation. Both
HSATII RNA and demethylated HSATII
DNA impact the nuclear distribution of
two classes of important epigenetic
regulators, corralling them into two types
of aberrant nuclear bodies and reducing
their accessibility to the rest of the nu-
cleus. These findings support a major
concept for the biological importance
of HSATII pericentric satellites, and their
misregulation in cancer, whereby these
exceptionally high-copy small tandem re-
peats, at both the DNA and RNA levels,
can act as a molecular ‘‘sponge,’’ which
impacts the distribution of epigenetic
regulators throughout the nuclear epige-
nome. This paves the way for avenues
of investigation into HSATII contribu-
tion to epigenomic regulation within nu-
clear structure, in cancer and possibly
development.
While studying repetitive CoT-1 RNAs,
we independently discovered HSATII
RNAs in cancers, and our results now
affirm Ting et al. (2011) who reported
abundant HSATII in RNA sequencing
(RNA-seq) data from pancreatic cancer.
Our study extends far beyond the initial observation of HSATII
RNA expression to illuminate the fundamental biology in several
major ways, giving rise to a concept for the potential significance
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of HSATII changes via impact on the epigenome. We examined
three satellite families (a-SAT, HSATII, and HSATIII) in an array of
tumor types and found preferential expression of HSATII. Zhu
et al. (2011) reported a-SAT expression in BRCA1-dependent
breast cancers and concluded this was due to BRCA1 loss.
However, that study did not examine BRCA1+ tumors for com-
parison. Our work clarifies that satellite misregulation is wide-
spread in many tumors, irrespective of whether tumors maintain
BRCA1, and HSATII RNA was more frequently expressed.
This study provides a conceptual framework to investigate
HSATII biology but also demonstrates a powerful approach to
study satellites, which can reveal biological relationships that
would escape other approaches. Study of such highly repetitive
sequences is notoriously difficult by standard genomic ap-
proaches. The abundance of these simple repeats makes
contamination a nearly intractable problem during extraction (re-
viewed in Vourc’h and Biamonti, 2011), hence HSATII DNA and
RNA hybridsmay form in vitro rather than being generated in vivo
by a postulated reverse transcriptase (Bersani et al., 2015).
Earlier evidence suggested that duplex molecules of highly re-
petitive sequences were impossible to avoid during RNA extrac-
tions (Fedoroff et al., 1977). Similarly, the abundance of HSATII
RNA specifically in cancer may also complicate quantification
of extracted satellite DNA. Using in situ hybridization, we were
able to study the 1q12 satellite (not in the genome build) and
found no substantial HSATII amplification within existing loci.
Biology and Significance of Human Satellite II
The study of pericentric HSATII has lagged far behind the rest of
the genome, but our results provide evidence for its biological
significance, based on its capacity to amass and sequester cyto-
logical scale (i.e., huge) accumulations of epigenetic factors.
Theoretically, if each 26-bp HSATII repeat in the two largest
(6 Mb) 1q12 loci could bind PRC1, just this locus alone could
Figure 7. Demethylated HSATII DNA and
Aberrant HSATII RNA Foci Can Sequester
Copious Epigenetic Factors and Impact
the Genomic Balance of Heterochromatin
Marks
HSATII DNA loci in normal cells are methylated,
ubiquitinated, and repressed. When HSATII DNA
becomes demethylated, PRC1 proteins aggregate
specifically at HSATII mega-satellite on 1q12 (and
sometimes 16q11), where it increases UbH2A
levels and maintains repression. Meanwhile, other
HSATII loci in the nucleoplasm lower in PRC1
become derepressed and begin to express HSATII
RNA, which, in turn, binds large amounts of
MeCP2. Thus, high-copy HSATII DNA and RNA
can accumulate large amounts of epigenetic
factors into cancer-associated PcG (CAP) bodies
and cancer-associated satellite transcript (CAST)
bodies and impact their accessibility in the cancer
epigenome.
corral roughly 0.5 3 106 such factors.
Our results also indicate that the reason
PRC1 ‘‘piles up’’ on HSATII at 1q12
(disproportionately to size) is likely because it contains sequence
subtypes not significantly detected on other chromosomes.
Similarly, abundant HSATII repeat RNAs aggregated into large
nuclear foci can also act as sponges for MeCP2 in cancer nuclei.
The effects of HSATII on PRC1 andMeCP2may be the ‘‘tip of the
iceberg,’’ as these and other repeat sequences (half the genome)
could potentially impact distribution of many chromatin regula-
tory factors.
This connection between HSATII DNA methylation and PcG
distribution has similarities to findings in normal mouse embry-
onic stem cells (ESCs) (Cooper et al., 2014), which showed
that induced demethylation of mouse major-satellite DNA trig-
gers recruitment of PRC1 and PRC2 to all mouse pericentro-
meres. PcG factors were also drawn away from canonical
gene targets, bolstering the premise here that sequestration of
factors on satellite repeats can impact other regions of the epige-
nome. However, there are interesting differences between our
findings in human and those in mouse. In human, PRC1 prefer-
entially localizes to the singular pericentric HSATII locus on
1q12 rather than all pericentromeres as in mice. Also, we gener-
ally did not find PRC2 accumulated with PRC1 on satellites as
seen in mouse, although our results suggest PRC2 may be
required for CAP body formation. Most importantly, findings
here show that CAP body formation at 1q12 occurs naturally
in vivo, is not a ‘‘normal’’ nuclear structure, and is a hallmark of
cancer seen in many tumors.
Given that this relationship to 1q12 is seen in vivo, albeit in a
disease context, we postulate that it may have a normal function
during development, such as global epigenomic programming
in early development, or gametogenesis. Hypomethylation of
satellites has been reported to be a hallmark of gametes, preim-
plantation embryonic cells, and extraembryonic tissues (e.g.,
Kaneda et al., 2011; Zagradisnik and Kokalj-Vokac, 2000). Simi-
larly, HSATII RNA foci may have some normal role during
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development or in specific cell types, potentially impacting distri-
bution of MeCP2 or other regulators. Satellites have been re-
ported to be transcribed in testis, brain, undifferentiated ESCs,
and pre-implantation embryos (Walton et al., 2014). Although
MeCP2 is known to be a methyl-DNA ‘‘reader’’ mutated in
Rhett’s syndrome, our findings bolster evidence that MeCP2
also binds RNA (Long et al., 2011; Young et al., 2005), and the
specific affinity for HSATII RNA (contrasted to a-Sat) may be to
regulate MeCP2 rather than visa versa.
HSATII DNA and Epigenetic Instability in Cancer
DNAmethylation and PcG proteins are heavily studied in cancer,
but the frequent hypomethylation of HSATII is not known to have
a functional impact. The HSATII biology shown here provides
a nexus between changes in DNA methylation and polycomb
repression (e.g., UbH2A). The 1q12 ‘‘mega-satellite’’ may play
a particular role, as increased copies of 1q are especially
frequent in cancer, particularly breast (Mertens et al., 1997).
Our findings indicate that HSATII demethylation and 1q12 copy
number not only may be caused by, but may contribute to epige-
netic instability in cancer, possibly providing a survival advan-
tage (e.g., a bigger ‘‘sponge’’ for PcG proteins).
HSATII demethylation and consequent CAP body formation
are associated with aberrant distribution of ubH2AK119 more
broadly. These observations shed light on the unexplained link
between global DNA hypomethylation and derepression of spe-
cific polycomb target genes (Jin et al., 2008; Reddington et al.,
2013) and may also explain why derepression of PcG-targeted
genes in ICF cells (or hypomethylatedmouse cells) did not corre-
late with demethylation of gene promoters (as expected) but with
dramatic changes in their histonemodifications (Jin et al., 2008).
Hence, the collective evidence supports the possibility these
changes in HSATII could further compromise heterochromatin
on a broader scale. Based on knowledge of the inactive X chro-
mosome, loss of a single repressive histone mark would not be
expected to result in immediate reactivation, sincemultiple chro-
matin modifications act synergistically to repress chromatin
(Csankovszki et al., 2001). Instead, ‘‘leaky’’ maintenance and
sporadic activation of different PcG-regulated genes would
occur in individual cells. We suggest this would generate a diver-
sity of expression profiles with more opportunity for those that
favor neoplastic progression (Carone and Lawrence, 2013;
Timp and Feinberg, 2013), as changes in PcG-regulated genes
(Wang et al., 2015) and in UbH2A distribution can impact onco-
genesis (Bhatnagar et al., 2014). Stochastic reactivation and
clonal selection may also explain why not all HSATII loci express
in the nucleoplasm low in PRC1 and why expression appears
locus specific for a given tumor.
In this context, it is striking to consider that, in a number of
HSATII RNA positive tumors, cells throughout a given tumor
show homogeneity of phenotype with respect to the number of
HSATII RNA foci and particular loci expressed. Such results
argue against this being a simple stochastic mismanagement
of the cancer epigenome in different cells of a tumor but rather
indicate a clonal expansion of an early expression profile.
Although it remains to be determined whether some satellite
expression can contribute to a selective advantage, we found
the chr7 locus expressed in multiple tumors in a small sample,
and several studies have reported amplification of chr7 pericen-
tromere is common and may be a neoplastic ‘‘driver’’ in many
types of solid tumors (including 80% of metaplastic breast
cancers) (e.g., Reis-Filho et al., 2006; Sanson et al., 2011). We
would also argue that the prevalence of PRC1 ‘‘capping’’ 1q12
in 50% of tumors is clearly non-random, and thus early loss
of DNA methylation on HSATII could promote sporadic reactiva-
tion of PcG-regulated genes/loci in individual cells, any one
of which might favor inappropriate growth and neoplastic
progression.
‘‘Toxic Repeat RNAs’’ in Cancer Can Impact Epigenetic
Regulators
This study provides evidence that the HSATII RNA expressed in
cancer is not just an inert biomarker of epigenetic dysregulation
but can accumulate MeCP2 (and likely other regulatory factors)
into aberrant nuclear bodies, possibly contributing to further
epigenetic changes. HSATII RNA foci are highly reminiscent of
nuclear ‘‘toxic repeat RNAs’’ in certain triplet repeat expansion
disorders (myotonic dystrophy type I), in which sequestration
of alternative splicing factors by repeat RNA is key to disease pa-
thology (Sicot and Gomes-Pereira, 2013). Sequestration of
MeCP2 is unlikely to be innocuous, as MeCP2 is a broad regu-
lator, including miRNA processing (Woo and Kim, 2014) and
LINE-1 repression (Yu et al., 2001), which is inappropriately ex-
pressed in many cancers (Carreira et al., 2014; Rodic and Burns,
2013). This would explain why we see increased L1 RNA in our
cancer samples and why Ting et al. (2011) noted L1 was overex-
pressed in cancers expressing HSATII.
Finally, these findings also have potential implications for
cancer diagnosis and treatment. First, cancer-specific bodies
discovered heremay provide biomarkers of epigenetic instability
with potential prognostic utility. These bodies can be seen in a
single cell of a pathology specimen, and our survey of tumors
provides a preliminary indication that this is more common in
higher-grade tumors. It is also notable that the demethylating
agents used here are in clinical development for cancer therapy
(to reactivate tumor suppressor genes) (Kelly et al., 2010); how-
ever, our results caution that demethylation of repeat sequences
can impact master epigenetic regulators and amplify effects on
the nuclear epigenome.
EXPERIMENTAL PROCEDURES
Cell Lines, Growth Conditions, and Fixation
All cell lines (listed in Supplemental Information) were grown in conditions rec-
ommended by suppliers (ATCC, Cambrex, and Coriell). 5-aza-20deoxycytidine
(0.2 mg/mL) and 3-deazaneplanocin A (EZH2 inhibitor) (5 mM) were added fresh
daily to asynchronously growing cultures. Our standard fixation protocols have
been detailed previously (Byron et al., 2013; Johnson et al., 1991; Tam et al.,
2002) (details in Supplemental Information).
FISH and IF
Our standard hybridization conditions for RNA, DNA, simultaneous DNA/RNA,
and simultaneous DNA or RNA and IF detection was performed as previously
described (e.g., Byron et al., 2013) (details in Supplemental Information). Sat2-
24nt LNA oligo was used for most images unless otherwise indicated. List of
probes are in the Supplemental Information. Oligos were usually hybridized
at 15% formamide, unless higher-stringency hybridizations were needed
(40% and 50% formamide).
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RNA-IP
RIPs were carried out essentially as described (Jones et al., 1998; Long et al.,
2011) (details in Supplemental Information).
ChIP-Seq and ChIP-PCR
ChIP-seq and Illumina paired-end deep sequencing were performed as
previously described (Yildirim et al., 2011) with some modification (details in
Supplemental Information). Deep sequencing data were mapped to human
genome build hg19 using Bowtie. Data normalization and peak calling were
performed over a 10-kb sliding window using SeqMonk.
Statistics
For the ChIP qPCR data, 95% confidence intervals were calculated (p < 0.05)
when comparing between groups (treated and control). Data including error
bars of 95% confidence for b-actin gene are shown. ChIP-seq peaks were
computed assuming a Poisson distribution and a cutoff of p < 10–5. Peak
overlap defined to be within 50 bp of each summit. p values for disease
ontology enrichment were computed using a binomial distribution, corrected
for multiple hypothesis testing by the Benjamini and Hochberg procedure.
Microscopy and Digital Imaging
An Axiovert 200 Zeiss microscope was used equipped with a 1003 PlanApo
objective (numerical aperture [NA] 1.4) and Chroma 83000 multi-band-pass
dichroic and emission filter sets, set up in a wheel to prevent optical shift.
Images were captured with the Zeiss AxioVision software and an Orca-ER
camera.
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The accession numbers for the UbH2A ChIP-seq data reported in this
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